BIOTRONIK Announces First Enrollments to BIOVITESSE Trial
BIOTRONIK has announced the start of enrollment of a coronary stent trial aiming at assessing the safety and clinical pe…
BIOTRONIK has announced the start of enrollment of a coronary stent trial aiming at assessing the safety and clinical pe…
BIOTRONIK’s exclusive rate responsive technology, Closed Loop Stimulation (CLS) has shown to reduce fainting in pacemake…
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce…
The European Heart Rhythm Association (EHRA) released the analytical supplement to the 10th EHRA White Book during the E…
Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause mortality and hospitali…
Die Auswertung der CASTLE-AF (Catheter Ablation versus Standard Conventional Treatment in Patients with Left Ventricular…
Cardiology experts will present conclusive results from various BIOTRONIK studies at the European Society of Cardiology’…
BIOTRONIK has announced the launch of its Evity cardiac resynchronization therapy pacemaker (CRT-P) in the Japanese mark…
BIOTRONIK’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the…
PRO-Kinetic Energy Cobalt Chromium (CoCr) Coronary Stent System from BIOTRONIK gained FDA approval utilizing results fro…